Welcome to a new Mercodia Webinar, on glucagon and liver disease, with Dr. Nicolai Wewer Albrechtsen
Our quest to offer new and exciting scientific content to our followers continues, and this time we are proud to introduce Dr. Nicolai J. Wewer Albrechtsen as our next speaker.
Dr. Wewer Albrechtsen earned his MD at the University of Copenhagen in 2014. Since 2011, he has been working on gastrointestinal hormones and in particular glucagon biology. In recent years, Dr. Wewer Albrechtsen has initiated his own scientific group that investigates the actions of glucagon in dysmetabolic conditions such as diabetes, obesity, and NAFLD with the use of state-of-art technologies including mass spectrometry. The group currently focuses on exploring a new physiological term known as glucagon resistance, identified in mice and humans with NAFLD.
During the webinar, Dr. Wewer Albrechtsen will discuss current data for how hyperglucagonemia may or may not mark a disrupted liver-alpha cell axis.
Watch the webinar Hyperglucagonemia – A disrupted liver-alpha cell crosstalk in fatty liver disease
